Innovative drugs helping plan members manage chronic conditions

Many plan members with diabetes struggle with adherence to daily insulin injections and research has found the majority of patients wish they could achieve the same control over their condition with fewer injections.

This session was made possible by Boehringer-Ingelheim Canada, Merck Canada Inc. and Novo Nordisk.

Read session coverage

High-cost drug claims lead to 20-times greater cost per claim for small plan sponsors

A recent survey by Innovative Medicines Canada found there are growing listing delays among Canada’s private drug plans.

Read session coverage

How preferred pharmacy networks can lower drug plan costs, boost access to care

Pharmacists are now uniquely positioned to support Canadians at a time when the public health-care system is stretched thin, creating significant barriers for people looking to access care.

Read session coverage

A closer look at growing asthma drug spend

Many Canadians living with asthma are experiencing poor control over their symptoms, impacting the workplace.

Read session coverage

How plan sponsors can improve employee health outcomes while optimizing drug plan spend

With chronic conditions growing in prevalence among plan members, plan sponsors have their work cut out for them in designing benefits plans that provide adequate health support and employee satisfaction while also being cost effective.

Read session coverage

Examining the link between cardiovascular disease, diabetes and obesity

While medications for three interconnected chronic conditions — cardiovascular disease, diabetes and obesity — represent a growing proportion of employers’ drug spend, there’s plenty that can be done to help employees’ slow the progression of these conditions while managing drug plan costs.

Read session coverage

How plan sponsors can use biosimilars to support employee health, reduce drug costs

Despite the safety and efficacy of biosimilars — and the potential cost savings they offer — uptake among private payers has been low historically and is only starting to gain steam.

Read session coverage

Plan sponsors, private payers can work together to help employees with rare diseases access novel treatments

It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans.

Read session coverage